In oncology, PET radiopharmaceuticals based on FAP inhibitors (FAPI) have shown high tumor-to-background contrast, consistent with the observation that FAP-positive cancer-associated fibroblasts are present in the stroma of a vast majority of epithelial tumors [15]. The gene discussed is FAP; the disease is neoplasm.